$MOH
MOLINA HEALTHCARE, INC.

2023 Q2 Form 10-Q Financial Statement

#000117992923000069 Filed on April 27, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $8.327B $8.149B
YoY Change 3.39% 4.88%
Cost Of Revenue $7.038B $6.871B
YoY Change 2.42% 4.69%
Gross Profit $1.289B $1.278B
YoY Change 9.05% 5.88%
Gross Profit Margin 15.48% 15.68%
Selling, General & Admin $787.0M $763.0M
YoY Change 2.74% -2.05%
% of Gross Profit 61.06% 59.7%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $42.00M $44.00M
YoY Change -4.55% 10.0%
% of Gross Profit 3.26% 3.44%
Operating Expenses $829.0M $807.0M
YoY Change 2.35% -1.47%
Operating Profit $460.0M $455.0M
YoY Change 27.42% 22.31%
Interest Expense -$27.00M $28.00M
YoY Change -200.0% 0.0%
% of Operating Profit -5.87% 6.15%
Other Income/Expense, Net -$27.00M -$28.00M
YoY Change 0.0% 0.0%
Pretax Income $416.0M $427.0M
YoY Change 24.55% 24.13%
Income Tax $107.0M $106.0M
% Of Pretax Income 25.72% 24.82%
Net Earnings $309.0M $321.0M
YoY Change 24.6% 24.42%
Net Earnings / Revenue 3.71% 3.94%
Basic Earnings Per Share $5.37 $5.58
Diluted Earnings Per Share $5.34 $5.52
COMMON SHARES
Basic Shares Outstanding 58.30M shares 57.90M shares
Diluted Shares Outstanding 57.90M shares 58.00M shares

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.796B $8.364B
YoY Change 11.64% 7.34%
Cash & Equivalents $4.910B $4.554B
Short-Term Investments $3.886B $3.810B
Other Short-Term Assets $260.0M $259.0M
YoY Change 22.07% 30.81%
Inventory
Prepaid Expenses
Receivables $2.385B $2.536B
Other Receivables $0.00 $0.00
Total Short-Term Assets $11.44B $11.16B
YoY Change 10.73% 9.98%
LONG-TERM ASSETS
Property, Plant & Equipment $285.0M $274.0M
YoY Change -28.93% -30.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $587.0M $119.0M
YoY Change 204.15% -34.25%
Total Long-Term Assets $2.220B $2.212B
YoY Change -0.89% -0.09%
TOTAL ASSETS
Total Short-Term Assets $11.44B $11.16B
Total Long-Term Assets $2.220B $2.212B
Total Assets $13.66B $13.37B
YoY Change 8.66% 8.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $857.0M $787.0M
YoY Change 19.86% -2.72%
Accrued Expenses
YoY Change
Deferred Revenue $414.0M $654.0M
YoY Change 3084.62% 3533.33%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.537B $7.614B
YoY Change 4.32% 8.14%
LONG-TERM LIABILITIES
Long-Term Debt $2.381B $2.177B
YoY Change 9.47% 0.14%
Other Long-Term Liabilities $122.0M $88.00M
YoY Change -3.17% -34.33%
Total Long-Term Liabilities $2.503B $2.265B
YoY Change 8.78% -1.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.537B $7.614B
Total Long-Term Liabilities $2.503B $2.265B
Total Liabilities $10.04B $10.08B
YoY Change 3.06% 5.4%
SHAREHOLDERS EQUITY
Retained Earnings $3.426B $3.117B
YoY Change 26.56% 17.31%
Common Stock $341.0M $296.0M
YoY Change 35.86% 35.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.621B $3.288B
YoY Change
Total Liabilities & Shareholders Equity $13.66B $13.37B
YoY Change 8.66% 8.18%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income $309.0M $321.0M
YoY Change 24.6% 24.42%
Depreciation, Depletion And Amortization $42.00M $44.00M
YoY Change -4.55% 10.0%
Cash From Operating Activities $487.0M $916.0M
YoY Change 32.34% 152.34%
INVESTING ACTIVITIES
Capital Expenditures $31.00M $32.00M
YoY Change -214.81% 39.13%
Acquisitions $0.00
YoY Change
Other Investing Activities -$106.0M -$5.000M
YoY Change -83.39% -138.46%
Cash From Investing Activities -$137.0M -$302.0M
YoY Change -79.4% -508.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00M -$65.00M
YoY Change -105.24% -15.58%
NET CHANGE
Cash From Operating Activities 487.0M $916.0M
Cash From Investing Activities -137.0M -$302.0M
Cash From Financing Activities 10.00M -$65.00M
Net Change In Cash 360.0M $549.0M
YoY Change -173.77% 52.5%
FREE CASH FLOW
Cash From Operating Activities $487.0M $916.0M
Capital Expenditures $31.00M $32.00M
Free Cash Flow $456.0M $884.0M
YoY Change 15.44% 160.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001179929
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0 usd
CY2022Q1 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0 usd
CY2022Q1 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0 usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-31719
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
MOLINA HEALTHCARE, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-4204626
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Oceangate
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.58
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Long Beach,
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90802
CY2023Q1 dei City Area Code
CityAreaCode
562
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
435-3666
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 Par Value
CY2023Q1 dei Trading Symbol
TradingSymbol
MOH
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58300000 shares
CY2023Q1 us-gaap Premiums Earned Net
PremiumsEarnedNet
7885000000 usd
CY2022Q1 us-gaap Premiums Earned Net
PremiumsEarnedNet
7531000000 usd
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 segment
CY2023Q1 moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
172000000 usd
CY2022Q1 moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
208000000 usd
CY2023Q1 us-gaap Net Investment Income
NetInvestmentIncome
71000000 usd
CY2022Q1 us-gaap Net Investment Income
NetInvestmentIncome
11000000 usd
CY2023Q1 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
21000000 usd
CY2022Q1 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
20000000 usd
CY2023Q1 us-gaap Revenues
Revenues
8149000000 usd
CY2022Q1 us-gaap Revenues
Revenues
7770000000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6871000000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6563000000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
591000000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
571000000 usd
CY2023Q1 moh Premium Tax Expenses
PremiumTaxExpenses
172000000 usd
CY2022Q1 moh Premium Tax Expenses
PremiumTaxExpenses
208000000 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
44000000 usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
40000000 usd
CY2023Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
16000000 usd
CY2022Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
16000000 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
7694000000 usd
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
7398000000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
455000000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
372000000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
28000000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
28000000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-28000000 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-28000000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
427000000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
344000000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
106000000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
86000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
321000000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
258000000 usd
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.45
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.52
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.39
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
321000000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
258000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
46000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-100000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
11000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-24000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
35000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-76000000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
356000000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
182000000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4554000000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4006000000 usd
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
3810000000 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
3499000000 usd
CY2023Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
2536000000 usd
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
2302000000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
259000000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
277000000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
11159000000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
10084000000 usd
CY2023Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
274000000 usd
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
259000000 usd
CY2023Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
1369000000 usd
CY2022Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
1390000000 usd
CY2023Q1 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
242000000 usd
CY2022Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
238000000 usd
CY2023Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
208000000 usd
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
220000000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
119000000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
123000000 usd
CY2023Q1 us-gaap Assets
Assets
13371000000 usd
CY2022Q4 us-gaap Assets
Assets
12314000000 usd
CY2023Q1 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3824000000 usd
CY2022Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3528000000 usd
CY2023Q1 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
2349000000 usd
CY2022Q4 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
2079000000 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
787000000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
889000000 usd
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
654000000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
359000000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7614000000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6855000000 usd
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2177000000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2176000000 usd
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
204000000 usd
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
215000000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
88000000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
104000000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
10083000000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
9350000000 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58000000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58000000 shares
CY2023Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
0 usd
CY2022Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
0 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
296000000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
328000000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-125000000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-160000000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
3117000000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2796000000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
3288000000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2964000000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13371000000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12314000000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2964000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
321000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
35000000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-32000000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
3288000000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2630000000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
258000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-76000000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-18000000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2794000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
321000000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
258000000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
44000000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
40000000 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-1000000 usd
CY2022Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-16000000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
25000000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
34000000 usd
CY2023Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
5000000 usd
CY2022Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-8000000 usd
CY2023Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
234000000 usd
CY2022Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-21000000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7000000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
32000000 usd
CY2023Q1 us-gaap Increase Decrease In Health Care Insurance Liabilities
IncreaseDecreaseInHealthCareInsuranceLiabilities
296000000 usd
CY2022Q1 us-gaap Increase Decrease In Health Care Insurance Liabilities
IncreaseDecreaseInHealthCareInsuranceLiabilities
263000000 usd
CY2023Q1 moh Increase Decrease In Medical Premium Liability Due To Agency
IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
270000000 usd
CY2022Q1 moh Increase Decrease In Medical Premium Liability Due To Agency
IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
137000000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-215000000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-81000000 usd
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
295000000 usd
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-352000000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
101000000 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
67000000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
916000000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
363000000 usd
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
646000000 usd
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
403000000 usd
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
371000000 usd
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
513000000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
32000000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23000000 usd
CY2023Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-5000000 usd
CY2022Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
13000000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-302000000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
74000000 usd
CY2023Q1 moh Common Stock Withheld To Settle Employee Tax Obligations
CommonStockWithheldToSettleEmployeeTaxObligations
58000000 usd
CY2022Q1 moh Common Stock Withheld To Settle Employee Tax Obligations
CommonStockWithheldToSettleEmployeeTaxObligations
52000000 usd
CY2023Q1 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
0 usd
CY2022Q1 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
20000000 usd
CY2023Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-7000000 usd
CY2022Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-5000000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-65000000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-77000000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
549000000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
360000000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4048000000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4506000000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4597000000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4866000000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4554000000 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4804000000 usd
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
43000000 usd
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
62000000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4597000000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4866000000 usd
CY2023Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
2536000000 usd
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
2302000000 usd
CY2023Q1 moh Medical Premiums Liability Medical Care Costs Threshold
MedicalPremiumsLiabilityMedicalCareCostsThreshold
1302000000 usd
CY2022Q4 moh Medical Premiums Liability Medical Care Costs Threshold
MedicalPremiumsLiabilityMedicalCareCostsThreshold
1145000000 usd
CY2023Q1 moh Amounts Due To Government Agencies Medicaid Other
AmountsDueToGovernmentAgenciesMedicaidOther
557000000 usd
CY2022Q4 moh Amounts Due To Government Agencies Medicaid Other
AmountsDueToGovernmentAgenciesMedicaidOther
482000000 usd
CY2023Q1 moh Amounts Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold
AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
85000000 usd
CY2022Q4 moh Amounts Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold
AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
84000000 usd
CY2023Q1 moh Amounts Due To Government Agencies Risk Adjustment And Part D Risk Sharing
AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
61000000 usd
CY2022Q4 moh Amounts Due To Government Agencies Risk Adjustment And Part D Risk Sharing
AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
76000000 usd
CY2023Q1 moh Other Medicare Program
OtherMedicareProgram
27000000 usd
CY2022Q4 moh Other Medicare Program
OtherMedicareProgram
27000000 usd
CY2023Q1 moh Amounts Dueto Government Agencies Risk Adjustment
AmountsDuetoGovernmentAgenciesRiskAdjustment
278000000 usd
CY2022Q4 moh Amounts Dueto Government Agencies Risk Adjustment
AmountsDuetoGovernmentAgenciesRiskAdjustment
230000000 usd
CY2023Q1 moh Amounts Due To Government Agencies Marketplace Medical Loss Ratio Threshold
AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
1000000 usd
CY2022Q4 moh Amounts Due To Government Agencies Marketplace Medical Loss Ratio Threshold
AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
2000000 usd
CY2023Q1 moh Amounts Dueto Government Agencies Other
AmountsDuetoGovernmentAgenciesOther
38000000 usd
CY2022Q4 moh Amounts Dueto Government Agencies Other
AmountsDuetoGovernmentAgenciesOther
33000000 usd
CY2023Q1 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
2349000000 usd
CY2022Q4 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
2079000000 usd
CY2023Q1 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
-278000000 usd
CY2023Q1 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
173000000 usd
CY2023Q1 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
105000000 usd
CY2022Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
-230000000 usd
CY2022Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
135000000 usd
CY2022Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
95000000 usd
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 15 years, or less than 15 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, U.S. Treasury securities, and corporate debt securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.</span></div>
CY2023Q1 moh Investments Maturity Period
InvestmentsMaturityPeriod
P15Y
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.58
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
321000000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
258000000 usd
CY2022Q4 moh Shares Outstanding Excluding Restricted Stock Awards
SharesOutstandingExcludingRestrictedStockAwards
57400000 shares
CY2021Q4 moh Shares Outstanding Excluding Restricted Stock Awards
SharesOutstandingExcludingRestrictedStockAwards
57900000 shares
CY2023Q1 moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
100000 shares
CY2022Q1 moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
100000 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57500000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58000000.0 shares
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
500000 shares
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
700000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58000000.0 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58700000 shares
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.45
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.52
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.39
CY2023Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
3810000000 usd
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
3499000000 usd
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
8000000 usd
CY2022Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
8000000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
3974000000 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000000 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
172000000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
3810000000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
3709000000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
212000000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
3499000000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
280000000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
277000000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
2340000000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
2245000000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
455000000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
443000000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
899000000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
845000000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
3974000000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
3810000000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
10000000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
1166000000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
25000000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
737 position
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
1800000000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
147000000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
923 position
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
1858000000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
77000000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
1116 position
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
1398000000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
135000000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
624 position
CY2023Q1 us-gaap Debt Securities Held To Maturity Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss
242000000 usd
CY2023Q1 us-gaap Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
123000000 usd
CY2023Q1 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
111000000 usd
CY2023Q1 us-gaap Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount
8000000 usd
CY2023Q1 us-gaap Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Claims incurred but not paid (“IBNP”)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,589 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,824 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,528 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div>
CY2023Q1 moh Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount
LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
2589000000 usd
CY2022Q4 moh Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount
LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
2597000000 usd
CY2023Q1 moh Pharmacy Claims Payable
PharmacyClaimsPayable
233000000 usd
CY2022Q4 moh Pharmacy Claims Payable
PharmacyClaimsPayable
206000000 usd
CY2023Q1 moh Capitation Claims Payable
CapitationClaimsPayable
95000000 usd
CY2022Q4 moh Capitation Claims Payable
CapitationClaimsPayable
94000000 usd
CY2023Q1 moh Other Claims Payable
OtherClaimsPayable
907000000 usd
CY2022Q4 moh Other Claims Payable
OtherClaimsPayable
631000000 usd
CY2023Q1 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3824000000 usd
CY2022Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3528000000 usd
CY2023Q1 moh Medical Claims And Benefits Payable
MedicalClaimsAndBenefitsPayable
493000000 usd
CY2022Q4 moh Medical Claims And Benefits Payable
MedicalClaimsAndBenefitsPayable
228000000 usd
CY2022Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3528000000 usd
CY2023Q1 us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
7169000000 usd
CY2023Q1 us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-298000000 usd
CY2023Q1 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
6871000000 usd
CY2023Q1 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
4487000000 usd
CY2023Q1 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
2358000000 usd
CY2023Q1 us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
6845000000 usd
CY2023Q1 moh Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions Net Of Post Closing Adjustments
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
0 usd
CY2023Q1 moh Medical Claims And Benefits Payable Adjustments Change In Provider
MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
270000000 usd
CY2023Q1 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3824000000 usd
CY2021Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3363000000 usd
CY2022Q1 us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
6769000000 usd
CY2022Q1 us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-206000000 usd
CY2022Q1 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
6563000000 usd
CY2022Q1 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
4197000000 usd
CY2022Q1 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
2199000000 usd
CY2022Q1 us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
6396000000 usd
CY2022Q1 moh Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions Net Of Post Closing Adjustments
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
-25000000 usd
CY2022Q1 moh Medical Claims And Benefits Payable Adjustments Change In Provider
MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
96000000 usd
CY2022Q1 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3601000000 usd
CY2023Q1 us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-298000000 usd
CY2022Q1 us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-206000000 usd
CY2023Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
23000000 usd
CY2022Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
24000000 usd
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2177000000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2176000000 usd
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 segment
CY2023Q1 us-gaap Revenues
Revenues
8149000000 usd
CY2022Q1 us-gaap Revenues
Revenues
7770000000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
455000000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
372000000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-28000000 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-28000000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
427000000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
344000000 usd

Files In Submission

Name View Source Status
0001179929-23-000069-index-headers.html Edgar Link pending
0001179929-23-000069-index.html Edgar Link pending
0001179929-23-000069.txt Edgar Link pending
0001179929-23-000069-xbrl.zip Edgar Link pending
exhibit101_firstamendmen.htm Edgar Link pending
exhibit101_firstamendmen001.jpg Edgar Link pending
exhibit101_firstamendmen002.jpg Edgar Link pending
exhibit101_firstamendmen003.jpg Edgar Link pending
exhibit101_firstamendmen004.jpg Edgar Link pending
exhibit101_firstamendmen005.jpg Edgar Link pending
exhibit101_firstamendmen006.jpg Edgar Link pending
exhibit101_firstamendmen007.jpg Edgar Link pending
exhibit101_firstamendmen008.jpg Edgar Link pending
exhibit101_firstamendmen009.jpg Edgar Link pending
exhibit101_firstamendmen010.jpg Edgar Link pending
exhibit101_firstamendmen011.jpg Edgar Link pending
exhibit101_firstamendmen012.jpg Edgar Link pending
exhibit101_firstamendmen013.jpg Edgar Link pending
exhibit101_firstamendmen014.jpg Edgar Link pending
exhibit101_firstamendmen015.jpg Edgar Link pending
exhibit101_firstamendmen016.jpg Edgar Link pending
exhibit101_firstamendmen017.jpg Edgar Link pending
exhibit101_firstamendmen018.jpg Edgar Link pending
exhibit101_firstamendmen019.jpg Edgar Link pending
exhibit101_firstamendmen020.jpg Edgar Link pending
exhibit101_firstamendmen021.jpg Edgar Link pending
exhibit101_firstamendmen022.jpg Edgar Link pending
exhibit101_firstamendmen023.jpg Edgar Link pending
exhibit101_firstamendmen024.jpg Edgar Link pending
exhibit101_firstamendmen025.jpg Edgar Link pending
exhibit101_firstamendmen026.jpg Edgar Link pending
exhibit101_firstamendmen027.jpg Edgar Link pending
exhibit101_firstamendmen028.jpg Edgar Link pending
exhibit101_firstamendmen029.jpg Edgar Link pending
exhibit101_firstamendmen030.jpg Edgar Link pending
exhibit101_firstamendmen031.jpg Edgar Link pending
exhibit101_firstamendmen032.jpg Edgar Link pending
exhibit101_firstamendmen033.jpg Edgar Link pending
exhibit101_firstamendmen034.jpg Edgar Link pending
exhibit101_firstamendmen035.jpg Edgar Link pending
exhibit101_firstamendmen036.jpg Edgar Link pending
exhibit101_firstamendmen037.jpg Edgar Link pending
exhibit101_firstamendmen038.jpg Edgar Link pending
exhibit101_firstamendmen039.jpg Edgar Link pending
exhibit101_firstamendmen040.jpg Edgar Link pending
exhibit101_firstamendmen041.jpg Edgar Link pending
exhibit101_firstamendmen042.jpg Edgar Link pending
exhibit101_firstamendmen043.jpg Edgar Link pending
exhibit101_firstamendmen044.jpg Edgar Link pending
exhibit101_firstamendmen045.jpg Edgar Link pending
exhibit101_firstamendmen046.jpg Edgar Link pending
exhibit101_firstamendmen047.jpg Edgar Link pending
exhibit101_firstamendmen048.jpg Edgar Link pending
exhibit101_firstamendmen049.jpg Edgar Link pending
exhibit101_firstamendmen050.jpg Edgar Link pending
exhibit101_firstamendmen051.jpg Edgar Link pending
exhibit101_firstamendmen052.jpg Edgar Link pending
exhibit101_firstamendmen053.jpg Edgar Link pending
exhibit101_firstamendmen054.jpg Edgar Link pending
exhibit101_firstamendmen055.jpg Edgar Link pending
exhibit101_firstamendmen056.jpg Edgar Link pending
exhibit101_firstamendmen057.jpg Edgar Link pending
exhibit101_firstamendmen058.jpg Edgar Link pending
exhibit101_firstamendmen059.jpg Edgar Link pending
exhibit101_firstamendmen060.jpg Edgar Link pending
exhibit101_firstamendmen061.jpg Edgar Link pending
exhibit101_firstamendmen062.jpg Edgar Link pending
exhibit101_firstamendmen063.jpg Edgar Link pending
exhibit101_firstamendmen064.jpg Edgar Link pending
exhibit101_firstamendmen065.jpg Edgar Link pending
exhibit101_firstamendmen066.jpg Edgar Link pending
exhibit101_firstamendmen067.jpg Edgar Link pending
exhibit101_firstamendmen068.jpg Edgar Link pending
exhibit101_firstamendmen069.jpg Edgar Link pending
exhibit101_firstamendmen070.jpg Edgar Link pending
exhibit101_firstamendmen071.jpg Edgar Link pending
exhibit101_firstamendmen072.jpg Edgar Link pending
exhibit101_firstamendmen073.jpg Edgar Link pending
exhibit101_firstamendmen074.jpg Edgar Link pending
exhibit101_firstamendmen075.jpg Edgar Link pending
exhibit101_firstamendmen076.jpg Edgar Link pending
exhibit101_firstamendmen077.jpg Edgar Link pending
exhibit101_firstamendmen078.jpg Edgar Link pending
exhibit101_firstamendmen079.jpg Edgar Link pending
exhibit101_firstamendmen080.jpg Edgar Link pending
exhibit101_firstamendmen081.jpg Edgar Link pending
exhibit101_firstamendmen082.jpg Edgar Link pending
exhibit101_firstamendmen083.jpg Edgar Link pending
exhibit101_firstamendmen084.jpg Edgar Link pending
exhibit101_firstamendmen085.jpg Edgar Link pending
exhibit101_firstamendmen086.jpg Edgar Link pending
exhibit101_firstamendmen087.jpg Edgar Link pending
exhibit101_firstamendmen088.jpg Edgar Link pending
exhibit101_firstamendmen089.jpg Edgar Link pending
exhibit101_firstamendmen090.jpg Edgar Link pending
exhibit101_firstamendmen091.jpg Edgar Link pending
exhibit101_firstamendmen092.jpg Edgar Link pending
exhibit101_firstamendmen093.jpg Edgar Link pending
exhibit101_firstamendmen094.jpg Edgar Link pending
exhibit101_firstamendmen095.jpg Edgar Link pending
exhibit101_firstamendmen096.jpg Edgar Link pending
exhibit101_firstamendmen097.jpg Edgar Link pending
exhibit101_firstamendmen098.jpg Edgar Link pending
exhibit101_firstamendmen099.jpg Edgar Link pending
exhibit101_firstamendmen100.jpg Edgar Link pending
exhibit101_firstamendmen101.jpg Edgar Link pending
exhibit101_firstamendmen102.jpg Edgar Link pending
exhibit101_firstamendmen103.jpg Edgar Link pending
exhibit101_firstamendmen104.jpg Edgar Link pending
exhibit101_firstamendmen105.jpg Edgar Link pending
exhibit101_firstamendmen106.jpg Edgar Link pending
exhibit101_firstamendmen107.jpg Edgar Link pending
exhibit101_firstamendmen108.jpg Edgar Link pending
exhibit101_firstamendmen109.jpg Edgar Link pending
exhibit101_firstamendmen110.jpg Edgar Link pending
exhibit101_firstamendmen111.jpg Edgar Link pending
exhibit101_firstamendmen112.jpg Edgar Link pending
exhibit101_firstamendmen113.jpg Edgar Link pending
exhibit101_firstamendmen114.jpg Edgar Link pending
exhibit101_firstamendmen115.jpg Edgar Link pending
exhibit101_firstamendmen116.jpg Edgar Link pending
exhibit101_firstamendmen117.jpg Edgar Link pending
exhibit101_firstamendmen118.jpg Edgar Link pending
exhibit101_firstamendmen119.jpg Edgar Link pending
exhibit101_firstamendmen120.jpg Edgar Link pending
exhibit101_firstamendmen121.jpg Edgar Link pending
exhibit101_firstamendmen122.jpg Edgar Link pending
exhibit101_firstamendmen123.jpg Edgar Link pending
exhibit101_firstamendmen124.jpg Edgar Link pending
exhibit101_firstamendmen125.jpg Edgar Link pending
exhibit101_firstamendmen126.jpg Edgar Link pending
exhibit101_firstamendmen127.jpg Edgar Link pending
exhibit101_firstamendmen128.jpg Edgar Link pending
exhibit101_firstamendmen129.jpg Edgar Link pending
exhibit101_firstamendmen130.jpg Edgar Link pending
exhibit101_firstamendmen131.jpg Edgar Link pending
exhibit101_firstamendmen132.jpg Edgar Link pending
exhibit101_firstamendmen133.jpg Edgar Link pending
exhibit101_firstamendmen134.jpg Edgar Link pending
exhibit101_firstamendmen135.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
moh-20230331.htm Edgar Link pending
moh-20230331.xsd Edgar Link pending
moh-20230331_g1.jpg Edgar Link pending
moh1q23_ex311.htm Edgar Link pending
moh1q23_ex312.htm Edgar Link pending
moh1q23_ex321.htm Edgar Link pending
moh1q23_ex322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
moh-20230331_lab.xml Edgar Link unprocessable
moh-20230331_cal.xml Edgar Link unprocessable
moh-20230331_def.xml Edgar Link unprocessable
moh-20230331_pre.xml Edgar Link unprocessable
moh-20230331_htm.xml Edgar Link completed
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable